Skip to content
Inamrinone
Amrinone, Inocor (inamrinone) is a small molecule pharmaceutical. Inamrinone was first approved as Inocor on 1984-07-31. It is used to treat cardiogenic shock, dilated cardiomyopathy, heart failure, and low cardiac output in the USA. The pharmaceutical is active against cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B and cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
cardiovascular diseasesD002318
hereditary congenital and neonatal diseases and abnormalitiesD009358
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Inamrinone lactate
Tradename
Company
Number
Date
Products
INOCORSanofiN-018700 DISCN1984-07-31
1 products
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
cardiogenic shock—D012770R57.0
dilated cardiomyopathyEFO_0000407D002311I42.0
heart failureEFO_0003144D006333I50
low cardiac output—D002303—
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C01: Cardiac therapy drugs
— C01C: Cardiac stimulants excl. cardiac glycosides
— C01CE: Phosphodiesterase inhibitors, cardiac stimulant
— C01CE01: Amrinone
HCPCS
No data
Clinical
Clinical Trials
32 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
DepressionD003863F33.9111115
Dysthymic disorderD019263EFO_0008623F34.111—2—3
PolyneuropathiesD011115EFO_0009562A69.22———1—1
Major depressive disorderD003865EFO_0003761F22———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Stress urinary incontinenceD014550HP_00109921—2——3
Cardiovascular diseasesD002318EFO_0000319I98—12——3
Heart diseasesD006331EFO_0003777I51.9—12——3
Cardiac arrhythmiasD001145EFO_0004269I49.9—12——3
Ventricular fibrillationD014693EFO_0004287I49.01——2——2
Ventricular tachycardiaD017180I47.2—11——2
DementiaD003704F03——1——1
Psychophysiologic disordersD011602F45.9——1——1
SchizophreniaD012559EFO_0000692F20——1——1
Anxiety disordersD001008EFO_0006788F41.1——1——1
Show 8 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
GlioblastomaD005909EFO_0000515—1———1
Somatoform disordersD013001F45—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PhotochemotherapyD0107782————2
Fecal incontinenceD005242R151————1
Breast neoplasmsD001943EFO_0003869C501————1
Actinic keratosisD055623L57.01————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Treatment-resistant depressive disorderD061218————11
PainD010146EFO_0003843R52————11
MyalgiaD063806HP_0003326M79.1————11
FibromyalgiaD005356EFO_0005687M79.1————11
Oxidative stressD018384EFO_1001905————11
Healthy volunteers/patients—————11
Panic disorderD016584EFO_0004262F41.0————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameINAMRINONE
INNamrinone
Description
Amrinone is a 3,4'-bipyridine substituted at positions 5 and 6 by an amino group and a keto function respectively. A pyridine phosphodiesterase 3 inhibitor, it is a drug that may improve the prognosis in patients with congestive heart failure. It has a role as an EC 3.1.4.* (phosphoric diester hydrolase) inhibitor.
Classification
Small molecule
Drug classcardiotonics (amrinone type)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Nc1cc(-c2ccncc2)c[nH]c1=O
Identifiers
PDB—
CAS-ID60719-84-8
RxCUI738
ChEMBL IDCHEMBL12856
ChEBI ID—
PubChem CID3698
DrugBankDB01427
UNII IDJUT23379TN (ChemIDplus, GSRS)
Target
Agency Approved
PDE3B
PDE3B
PDE3A
PDE3A
Organism
Homo sapiens
Gene name
PDE3B
Gene synonyms
NCBI Gene ID
5140
Protein name
cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B
Protein synonyms
CGI-PDE B, CGIP1, CGIPDE1, cGMP-inhibited 3',5'-cyclic phosphodiesterase B, Cyclic GMP-inhibited phosphodiesterase B, cyclic nucleotide phosphodiesterase, phosphodiesterase 3B, cGMP-inhibited
Uniprot ID
Q6SEI4
Mouse ortholog
Pde3b (18576)
cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B (Q61409)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 732 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
6,676 adverse events reported
View more details